Drug profile · INN
ruxolitinib
JAKAVI
ruxolitinib (JAKAVI) is a tyrosine-protein kinase jak2 inhibitor. Associated with Novartis Pharmaceuticals. Route of administration: oral. Current US regulatory status: approved.
Drug details — ruxolitinib
- US status
- approved
- Class
- Dermatologicals (D11)
- Route
- ORAL
- Patents
- 0
- Programs
- 41
- Data quality
- 0.84
Quick answer
ruxolitinib (JAKAVI) is a tyrosine-protein kinase jak2 inhibitor. Associated with Novartis Pharmaceuticals. Route of administration: oral. Current US regulatory status: approved.
Key facts
Mechanism of action
Tyrosine-protein kinase JAK2 inhibitor
Approval history
| Authority | Status | Date |
|---|---|---|
| FDA | approved | — |
| EMA | approved | — |
| TGA | approved | — |
| NMPA | clinical trials | — |
Recent coverage
Karyopharm's Selinexor Plus Ruxolitinib SENTRY Trial Data to be Presented at EHA 2026
Karyopharm's Phase 3 SENTRY trial evaluating selinexor in combination with ruxolitinib for myelofibrosis has been selected for a late-breaking oral presentation at EHA 2026. This presentation will feature results from the randomized, double-blind, placebo-controlled study.
FDA Approves Incyte's Jakafi XR Extended-Release Tablets for Myelofibrosis and Blood Disorders
Incyte receives FDA approval for once-daily Jakafi XR (ruxolitinib) extended-release tablets for myelofibrosis, polycythemia vera, and GVHD treatment.
FDA Approves Incyte's Jakafi XR Extended-Release Tablets for Myelofibrosis, Polycythemia Vera Treatment
Incyte receives FDA approval for Jakafi XR (ruxolitinib) extended-release tablets, offering improved dosing convenience for rare blood cancer patients.
Pipeline programs
Related & competitor drugs
Frequently asked questions
What is ruxolitinib?
ruxolitinib (JAKAVI) is a tyrosine-protein kinase jak2 inhibitor. Associated with Novartis Pharmaceuticals. Route of administration: oral. Current US regulatory status: approved.
What is the brand name for ruxolitinib?
JAKAVI is a marketed brand name for ruxolitinib. Check FDA Drugs@FDA for the current US label holder and prescribing information.
What is the US approval status of ruxolitinib?
ruxolitinib has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.